Eos Energy Enterprises Inc vs Viatris Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.53 (market cap $1.01B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 19.8× Eos Energy Enterprises Inc's market cap, and Viatris Inc pays a 2.75% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Viatris Inc for 57 Days on average.
| EOSE | VTRS | |
|---|---|---|
Market Cap | $1.01B | $20.03B |
Volume | 39,626,541 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $19.19 | $18.27 |
52-Week Low | $2.77 | $9.74 |
Typical Hold Time | 16 Days | 57 Days |
Enterprise Value | $1.34B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.575, down 16.94% in the last session, reflecting ongoing volatility despite positive business developments. The company shows rapid revenue growth with $214M projected for 2026 but faces significant profitability challenges with a -246.76% net income margin. Recent catalysts include an $87M Department of Energy loan advance and a major partnership with Google for a $350M West Virginia energy project announced September 2, 2026.
While analyst consensus remains cautiously optimistic with a $7.10 price target representing 176% upside, the stock carries substantial risk due to persistent losses and high debt-to-asset ratio of 91.87%. The technical picture is bearish with weak momentum, though oversold RSI levels may indicate potential for near-term bounce. Investment appeal hinges on successful execution of production scaling and path to profitability.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →